As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.
By Melanie Senior
On one level, it’s surprising that any company would want to pursue new treatments for cholesterol lowering and atherosclerosis. The...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.
Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.
